ARCHIVES

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

NIH Introduces “Modular” Gran Application And Awards

February 26, 1999

ODAC Recommends Fludarabine Approval for Refractory CLL

September 21, 1990

Duke University Settles 11 Medical Malpractice Cases Related to Potti’s trials

December 9, 2011

Obama Picks Hamburg for FDA Commissioner

March 20, 2009

“Realistic” Bypass Budget For 1983 asks $1.147Billion; Organ Site, Training, Control Would Get No Increases

September 18, 1981

ASCO Breaks Ground For New HQ.

August 4, 2006